Research Output per year
Fingerprint Dive into the research topics where Takanori Kanai is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 38 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output
10-Year Trends in Helicobacter pylori Eradication Rates by Sitafloxacin-Based Third-Line Rescue Therapy
Mori, H., Suzuki, H., Matsuzaki, J., Masaoka, T. & Kanai, T., 2020 Sep 1, In : Digestion. 101, 5, p. 644-650 7 p.Research output: Contribution to journal › Article
1
Citation
(Scopus)
5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis
Mizuno, S., Ono, K., Mikami, Y., Naganuma, M., Fukuda, T., Minami, K., Masaoka, T., Terada, S., Yoshida, T., Saigusa, K., Hirahara, N., Miyata, H., Suda, W., Hattori, M. & Kanai, T., 2020 Jan 1, In : Intestinal Research. 18, 1, p. 69-78 10 p.Research output: Contribution to journal › Article
Open Access
1
Citation
(Scopus)
A case of intrahepatic cholangiocellular carcinoma due to thorotrast deposition, well-controlled by radiofrequency ablation therapy
Taniki, N., Nakamoto, N., Yoshida, A., Chu, P. S., Ikura, A., Yamataka, K., Morikawa, R., Shiba, S., Yamaguchi, A., Usui, S., Ojiro, K., Ebinuma, H., Saito, H., Kubota, N., Masugi, Y., Sakamto, M. & Kanai, T., 2020, In : Acta Hepatologica Japonica. 61, 5, p. 262-269 8 p.Research output: Contribution to journal › Article
Open Access
Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn's disease in Japanese and Korean patients: The OPERA study
Saruta, M., Park, D. I., Kim, Y. H., Yang, S. K., Jang, B. I., Cheon, J. H., Im, J. P., Kanai, T., Katsuno, T., Ishiguro, Y., Nagaoka, M., Isogawa, N., Li, Y., Banerjee, A., Ahmad, A., Hassan-Zahraee, M., Clare, R., Gorelick, K. J., Cataldi, F., Watanabe, M. & 1 others, , 2020 Jan 1, In : Intestinal Research. 18, 1, p. 45-55 11 p.Research output: Contribution to journal › Article
Open Access
A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure–Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)
Suzuki, T., Sukawa, Y., Imamura, C., Masuishi, T., Satake, H., Kumekawa, Y., Funakoshi, S., Kotaka, M., Horie, Y., Kawai, S., Okuda, H., Terazawa, T., Kondoh, C., Kato, K., Yoshimura, K., Ishikawa, H., Hamamoto, Y., Boku, N., Takaishi, H. & Kanai, T., 2020 Mar, In : Clinical Colorectal Cancer. 19, 1, p. 13-21.e3Research output: Contribution to journal › Article